Literature DB >> 33165093

Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study.

Jennifer Pors1, Sheila Segura2, Derek S Chiu3, Noorah Almadani1, Hezhen Ren1, Daniel J Fix2, Brooke E Howitt4, David Kolin5, W Glenn McCluggage6, Jelena Mirkovic7, Blake Gilks1,8, Kay J Park2, Lynn Hoang1,8.   

Abstract

Mesonephric adenocarcinoma (MA) and mesonephric-like adenocarcinoma (MLA) are uncommon neoplasms of the gynecologic tract that have until recently been poorly understood. Although their morphologic, immunohistochemical, and molecular profiles have been recently defined, little is known about their clinical behavior. Small studies have demonstrated inconsistent findings and no large studies have examined the clinical behavior of these adenocarcinomas. In this multi-institutional study, representing the largest and most stringently defined cohort of cases to date, we examined the clinicopathologic features of 99 MAs and MLAs (30 MAs of the uterine cervix, 44 MLAs of the endometrium, and 25 MLAs of the ovary). Only tumors with characteristic mesonephric morphology and either immunohistochemical or molecular support were included. Our results demonstrate that the majority of mesonephric neoplasms presented at an advanced stage (II to IV) (15/25 [60%] MA of the cervix, 25/43 [58%] MLA of the endometrium, and 7/18 [39%] MLA of the ovary). The majority (46/89 [52%] overall, 12/24 [50%] MA of the cervix, 24/41 [59%] MLA of the endometrium, and 10/24 [42%] MLA of the ovary) developed recurrences, most commonly distant (9/12 [75%] MA of the cervix, 22/24 [92%] MLA of the endometrium, and 5/9 [56%] MLA of the ovary). The 5-year disease-specific survival was 74% (n=26) for MA of cervix, 72% (n=43) for MLA of endometrium, and 71% (n=23) for MLA of ovary. Our results confirm that mesonephric neoplasms are a clinically aggressive group of gynecologic carcinomas that typically present at an advanced stage, with a predilection for pulmonary recurrence.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33165093      PMCID: PMC7954854          DOI: 10.1097/PAS.0000000000001612

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  39 in total

1.  Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Authors:  Aline Talhouk; Melissa K McConechy; Samuel Leung; Winnie Yang; Amy Lum; Janine Senz; Niki Boyd; Judith Pike; Michael Anglesio; Janice S Kwon; Anthony N Karnezis; David G Huntsman; C Blake Gilks; Jessica N McAlpine
Journal:  Cancer       Date:  2017-01-06       Impact factor: 6.860

2.  Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (so-called mesonephromas).

Authors:  A L Herbst; R E Scully
Journal:  Cancer       Date:  1970-04       Impact factor: 6.860

3.  GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract.

Authors:  Brooke E Howitt; Megan M Emori; Ronny Drapkin; Cynthia Gaspar; Justine A Barletta; Marisa R Nucci; W Glenn McCluggage; Esther Oliva; Michelle S Hirsch
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

4.  Mesonephric adenocarcinomas of the uterine cervix and corpus: HPV-negative neoplasms that are commonly PAX8, CA125, and HMGA2 positive and that may be immunoreactive with TTF1 and hepatocyte nuclear factor 1-β.

Authors:  Sarah L Kenny; Hilary A McBride; Jackie Jamison; W Glenn McCluggage
Journal:  Am J Surg Pathol       Date:  2012-06       Impact factor: 6.394

5.  Five commonly used markers (p53, TTF1, CK7, CK20, and CK34betaE12) are of no use in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.

Authors:  Chih-Ping Han; Lai-Fong Kok; Ming-Yung Lee; Tina S Wu; Alexandra Ruan; Ya-Wen Cheng; Po-Hui Wang; Chiew-Loon Koo; Yeu-Sheng Tyan
Journal:  Arch Gynecol Obstet       Date:  2009-05-15       Impact factor: 2.344

6.  Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract.

Authors:  Jelena Mirkovic; Lynette M Sholl; Elizabeth Garcia; Neal Lindeman; Laura MacConaill; Michelle Hirsch; Paola Dal Cin; Melissa Gorman; Justine A Barletta; Marisa R Nucci; W Glenn McCluggage; Brooke E Howitt
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

7.  Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin.

Authors:  Moon-Young Kim; Heounjeong Go; Jaemoon Koh; Kyoungbun Lee; Hye-Sook Min; Min-A Kim; Yoon Kyung Jeon; Hye-Seung Lee; Kyung-Chul Moon; So Yeon Park; Woo-Ho Kim; Doo Hyun Chung
Journal:  Histopathology       Date:  2014-03-26       Impact factor: 5.087

8.  c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract.

Authors:  Jennifer Pors; Julie Ho; Leah Prentice; Emily Thompson; Dawn Cochrane; Evan Gibbard; David Huntsman; Blake Gilks; Lynn N Hoang
Journal:  Am J Surg Pathol       Date:  2020-04       Impact factor: 6.394

9.  Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.

Authors:  Jelena Mirkovic; Marie McFarland; Elizabeth Garcia; Lynette M Sholl; Neal Lindeman; Laura MacConaill; Fei Dong; Michelle Hirsch; Marisa R Nucci; Charles M Quick; Christopher P Crum; W Glenn McCluggage; Brooke E Howitt
Journal:  Am J Surg Pathol       Date:  2018-02       Impact factor: 6.394

10.  Clinicopathologic and Molecular Characteristics of Mesonephric Adenocarcinoma Arising From the Uterine Body.

Authors:  Kiyong Na; Hyun-Soo Kim
Journal:  Am J Surg Pathol       Date:  2019-01       Impact factor: 6.394

View more
  14 in total

Review 1.  Beyond Serous: Treatment Options for Rare Endometrial Cancers.

Authors:  Erin Crane
Journal:  Curr Treat Options Oncol       Date:  2022-10-07

2.  Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution.

Authors:  Tianshi Ma; Mengyu Chai; Huafeng Shou; Guoqing Ru; Ming Zhao
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

3.  Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome: A Comprehensive Analysis of 58 Cases.

Authors:  Simona Stolnicu; Georgia Karpathiou; Esther Guerra; Claudia Mateoiu; Armando Reques; Angel Garcia; Joost Bart; Ana Felix; Daniela Fanni; Joao Gama; David Hardisson; Jennifer A Bennett; Carlos Parra-Herran; Esther Oliva; Nadeem Abu-Rustum; Robert A Soslow; Kay J Park
Journal:  Am J Surg Pathol       Date:  2022-01-05       Impact factor: 6.298

4.  Mucinous Tumor Coexisting With Mesonephric-like Proliferation/Tumor in the Ovary: A Novel Association.

Authors:  Neshat Nilforoushan; Lian Liu; Gloria Cheang; Amy C Sui; John Andersen; Brian S Finkelman; Ying Liu; Niloofar Nasseri-Nik; Russell Vang; Brigitte M Ronnett; Wei Song; Deyin Xing
Journal:  Am J Surg Pathol       Date:  2022-04-12       Impact factor: 6.298

5.  Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics.

Authors:  Hyun Hee Koh; Eunhyang Park; Hyun-Soo Kim
Journal:  Diagnostics (Basel)       Date:  2022-01-27

Review 6.  Progress in the pathological arena of gynecological cancers.

Authors:  W Glenn McCluggage
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

7.  Serous Carcinoma of the Endometrium with Mesonephric-Like Differentiation Initially Misdiagnosed as Uterine Mesonephric-Like Adenocarcinoma: A Case Report with Emphasis on the Immunostaining and the Identification of Splice Site TP53 Mutation.

Authors:  Sangjoon Choi; Yoon Yang Jung; Hyun-Soo Kim
Journal:  Diagnostics (Basel)       Date:  2021-04-18

8.  Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma.

Authors:  Sherry Shen; Maria M Rubinstein; Kay J Park; Jason A Konner; Vicky Makker
Journal:  Gynecol Oncol Rep       Date:  2021-08-08

Review 9.  New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.

Authors:  Angela Santoro; Giuseppe Angelico; Antonio Travaglino; Frediano Inzani; Damiano Arciuolo; Michele Valente; Nicoletta D'Alessandris; Giulia Scaglione; Vincenzo Fiorentino; Antonio Raffone; Gian Franco Zannoni
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 10.  The Evolution of Ovarian Carcinoma Subclassification.

Authors:  Martin Köbel; Eun Young Kang
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.